Sir,
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity characterized by seizure, altered sensorium, visual disturbance and nausea, and vomiting, along with characteristic neuroimaging findings. Magnetic resonance imaging (MRI) often shows bilateral, symmetric areas of white matter edema predominantly in occipital and posterior parietal lobes.
Autoimmune diseases are associated with 8-10% of PRES cases. 1 
PRES has been reported in patients with systemic lupus erythematosus (SLE).
On the other hand, drugs, chiefly chemotherapeutic agents, immunosuppressive agent, and monoclonal antibodies including rituximab, are also considered as possible etiological agents. We report a patient of lupus nephritis who developed PRES following third dose of rituximab infusion.
A 17-year-old female was admitted with a flare of lupus nephritis. She was diagnosed as SLE with nephritis (class IV-A) about 2½ years previously and received cyclophosphamide according to NIH protocol followed by maintenance therapy with mycophenolate mofetil along with corticosteroid. She responded well but developed the current episode of nephritis flare while on regular maintenance therapy. Urine analysis showed active sediments with nephrotic range proteinuria (9.2 g/24 hours). She was started with rituximab (375 mg/m 2 of body surface area/week). Twelve hours after the third dose of rituximab she developed repeated attacks of convulsions, visual disturbances in the form of blurring of vision, and she was stuporous (Grady coma scale II and Glasgow coma scale 9). Blood pressure was 130/98 mmHg. Plantar reflexes were extensor bilaterally. No focal neurological signs were present. Fundoscopy and cerebrospinal fluid studies were normal. MRI of the brain was consistent with a diagnosis of PRES (Figure 1 ). She responded to conservative management and follow-up MRI after four weeks was normal. She was not given the fourth dose of rituximab.
Approximate prevalence of PRES among SLE patients is 0.69%. 2 PRES is found more commonly among Asian patients. Most of the patients are female with highly active disease and renal involvement. Most of them are also hypertensive (91.7%). 3 In an Indian cohort of 13 SLE patients, six had PRES as a part of their initial presentation of lupus. 4 PRES is more common among young lupus patients in the early part of the disease. Almost 90% patients show full recovery. 2 Our patient had most of these clinical parameters implicated in the development of PRES except for significant hypertension.
PRES following rituximab therapy has also been documented in the literature. 5, 6 Mavragani et al. reported PRES in a lupus nephritis patient following a third dose of rituximab infusion. 7 The exact pathogenesis of PRES following rituximab is not definitely known. Hypertensive crisis seen in few patients following rituximab therapy may be an important factor. 8 However, there was no such event in our patient. Endothelial activation by rituximab through CD20 binding may be another possible mechanism. 9 In this patient it was difficult to determine whether PRES was due to disease or drug. However, absence of significant hypertension, normal fundoscopic finding, and a clear temporal association between symptom development and rituximab infusion prompted us to withhold rituximab. We report this case as an example of a 
